Investors now have more reasons to doubt Harmoni's ability to show a survival benefit.
ApexOnco Front Page
Recent articles
Early data with IDE849 match those with Zai’s zocilurtatug pelitecan.
A single but durable stable disease sends the microcap's stock up 730%.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A newly published cache of CRLs includes six novel oncology drugs.
The deal for ISB 2001 is worth $700m up front.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
